Head and neck carcinoma (H&N). Salivary glands tumors are excluded.
Subject has a metal implant, including a programmable shunt, in the head or neck that is incompatible with MRI.
Patients must have an immune checkpoint resistant malignancy (for example, RCC, head and neck carcinoma or MSI high cancers which have approved settings for anti-PD treatment), confirmed histologically or cytologically.
Must be willing to undergo definitive resection with neck dissection.
COHORT II: Pathologically proven solid tumor in the head and neck that are amenable to palliative treatment
In the opinion of the local PI: Head and neck cancer patients with airway tumor recurrence that may compromise breathing or swallowing if inflammation or edema is transiently aggravated by Hiltonol injection. Head and neck cancer patients with tumor invading major blood vessels for whom there may be a risk of blockage or bleeding if inflammation or edema is transiently increased by Hiltonol injections.
Previous radical radiation therapy to the head and neck, excluding superficial radiation therapy to cutaneous SCC or basal cell carcinoma, which is not within or overlapping the tumour bed
Prior chemo therapy or radiosensitizer for head and neck cancer
Patients must be evaluated by a head and neck surgeon and be deemed surgically resectable at baseline
A previous diagnosis of histologically defined head and neck cancer.
The head and neck garments must fit appropriately. For patients with a tracheostomy, the fit will be assessed to ensure that the garments do not interfere with their tracheostomy.
Uncontrolled hyperthyroidism or parathyroidism (for which endocrinologist recommends against neck compression).
Facial or head and neck dermal metastasis.
No head and neck surgery of the primary tumor or lymph nodes except for incisional or excisional biopsies.
Surgical resection of head and neck must be planned, either as primary treatment or salvage; patients must undergo research biopsy prior to receiving drug
Malignancies resulting in cutaneous metastasis originating from: breast, lung, head and neck, pancreatic, urinary bladder, prostate, testicular, ovarian, uterine, cervical, gastric, adrenal, thyroid, parathyroid cancers, or other solid tumors which previously responded to taxane treatment;
Patients with distant metastatic disease (Mc) from the current head and neck cancer including brain metastasis
A history of metal in the head or eyes
Limited neck dissections retrieving ?  nodes are permitted and considered as non-therapeutic nodal excisions. Fine needle aspirations of the neck that are positive for squamous cell carcinoma are sufficient for diagnosis pending pathology review at participating institutions.
Examination by an ear/nose/throat (ENT) or head and neck surgeon, including laryngopharyngoscopy (mirror and/or fiberoptic and/or direct procedure) within  weeks prior to enrollment.
History of any other cancer other than head and neck cancer (HNC) (except carcinoma in situ of the cervix) within the last  years.
Patients treated with previous cranial or head/neck radiotherapy leading to radiation field overlap
Subjects must have histologically or cytologically confirmed recurrent head and neck cancer
Pathologically proven recurrent or second-primary head-and-neck cancer receiving prior radiotherapy with or without chemotherapy
Radiation therapy to head and neck (excluding eyes), and internal organs of chest, abdomen or pelvis in the month prior to enrollment
Having received radiation therapy to head and neck (excluding eyes), and internal organs of chest, abdomen or pelvis in the month prior to enrollment
ARM B COHORT : Patients with head and neck cancer must not have radiologic evidence of major arterial involvement
Subjects with a diagnosis of recurrent head and neck cancer
Determined by the treating physician to be a candidate for organ preserving, concurrent standard chemotherapy and radiation therapy to the head and neck with definitive intent
Neck adenopathy that involves the overlying skin
Initial surgical treatment including tonsillectomy or neck dissection, but excluding diagnostic biopsy of the primary site or nodal sampling of neck disease
Presence of N or N disease in neck dissection
Patients with stage III/IV per tumor/nodes/metastasis (TNM) guidelines for head and neck sites (American Joint Committee on Cancer [AJCC] th Edition), locally advanced, biopsy proven squamous cell cancer of the head and neck that undergo chemoradiation as their primary treatment with curative intent; patients with oropharynx (human papillomavirus [HPV] positive and HPV negative), hypopharynx, larynx primaries, nasopharynx as well as those with documented squamous cell cancer (SCC) of the cervical lymph nodes, with unknown primaries, are eligible
Patients who have received prior radiation to the head and neck or adjacent anatomical site (e.g., upper lobe lung, brain)
Histological or cytological documentation of recurrent head and neck cancer requiring regional therapy
Primaries on the torso, upper and lower extremities and head and neck region
Radiation therapy to head and neck (excluding eyes), and internal organs of chest, abdomen or pelvis in the month prior to enrollment
Previous head and neck surgery that would preclude transoral/robotic procedures; this is at the investigators discretion; this is not an exclusion criterion for the non-surgical arm
Head and neck oropharyngeal, hypopharyngeal, or oral cavity lesions requiring surgical resection, biopsy, or invasive treatment
Carotid artery involvement by tumor had a neck dissection on that side
All HNSCC lesions should be in the head and neck region and suitable for intra-tumoral injection
ORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Tumor involvement of the following sites or any of these signs or symptoms likely to be associated with Tb cancer:\r\n* Involvement of pterygopalatine fossa, maxillary sinus, or facial skin\r\n* Gross extension of tumor to the skull base\r\n* Pterygoid plate erosion\r\n* Sphenoid bone or foramen ovale involvement\r\n* Direct extension to involve prevertebral fascia\r\n* Extension to superior nasopharynx or Eustachian tube\r\n* Direct extension into the neck with involvement of the deep neck musculature (neck node fixation)\r\n* Suspected invasion (encasement) of the common or internal carotid arteries; encasement will be assessed radiographically and will be defined as tumor surrounding the carotid artery  degrees or greater\r\n* Direct extension of neck disease to involve the external skin\r\n* Direct extension to mediastinal structures\r\n* Regional metastases to the supraclavicular neck (low level VB and IVB)
HPV-ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA: Tumor involvement of the following sites or any of these signs or symptoms likely to be associated with Tb cancer:\r\n* Involvement of pterygopalatine fossa, maxillary sinus\r\n* Gross extension of tumor to the skull base\r\n* Pterygoid plate erosion\r\n* Sphenoid bone or foramen ovale involvement\r\n* Direct extension to involve prevertebral fascia\r\n* Extension to superior nasopharynx or Eustachian tube\r\n* Direct extension into the neck with involvement of the deep neck musculature (neck node fixation)\r\n* Suspected invasion (encasement) of the common or internal carotid arteries; encasement will be assessed radiographically and will be defined as tumor surrounding the carotid artery  degrees or greater\r\n* Direct extension of neck disease to involve the external skin\r\n* Direct extension to mediastinal structures\r\n* Regional metastases to the supraclavicular neck (low level VB and IVB)
Patients treated with previous cranial or head/neck radiotherapy leading to significant radiation field overlap.
Patients with oral cavity cancer are excluded from participation if resection of the primary tumor is considered technically feasible by an oral or head and neck cancers surgical subspecialist.
Patients with metastatic disease beyond the neck and supraclavicular region will be excluded
Prior chemotherapy or radiotherapy for the diagnosis of GBM or for cancers of the head and neck
Any head and neck subsite other than oropharynx (including unknown primary site)
Prior head and neck malignancy or history of other prior non-head and neck malignancy (excluding skin cancer and early stage treated prostate cancer) within the past  years
Patients with concurrent primary head and neck tumors that will be resected as part of treatment plan are considered eligible
Prior head and neck malignancy, or history of other prior non-head and neck malignancy within the past  years (excluding skin cancer and early stage treated prostate cancer)
Pathologically (histologically or cytologically) confirmed diagnosis of recurrent or second primary squamous cell carcinoma (SCC) of the oral cavity, oropharynx, hypopharynx, larynx, or recurrent neck metastases with unknown primary; exception from pathology confirmation of tumor recurrence is accepted for patients who originally had pathologically confirmed SCC of the Head and Neck, the new tumor is located in the head and neck area and it is clinically considered as a recurrence of the original tumor, and a tumor biopsy is technically difficult and would expose the patient to unjustified risk; the treating physicians should agree and document the clinical definition of tumor recurrence and should document the increased risk for biopsy
Unilateral neck radiation
Pathologically confirmed diagnosis of a recurrent or a new primary head and neck cancer
A history of prior radiation to the head and neck (>=  Gy, in  Gy/fraction equivalent)
Histologically or cytologically confirmed head and neck cancer of any other primary anatomic location in the head and neck not specified in the inclusion criteria including patients with SCCHN of unknown primary or non-squamous histologies (eg, nasopharynx or salivary gland)
Examination by an ENT or Head & Neck Surgeon including laryngopharyngoscopy prior to entering the study.
Patients with initial surgical treatment, radical or modified neck dissection.
direct extension into the neck with involvement of the deep neck musculature (neck node fixation);
direct extension of neck disease to involve the external skin;
regional metastases to the supraclavicular neck (low level IVB or VB)
Phase I run in: biopsy proven RMHNSCC with the following primary sites: nasopharynx, paranasal sinus, nasal cavity, skin/cutaneous sites; patients with unknown head and neck primary sites will be enrolled; patients with recurrent or metastatic squamous cell carcinomas of the head and neck (regardless of primary site) who are either unwilling to receive or have contraindications (deemed by treating physician) to standard systemic chemotherapy will also be eligible; patients with biopsy proven RMSGC be eligible as well
Physician recommendation of bilateral neck radiation
Must have a primary melanoma that is cutaneous (including head, neck, trunk, extremity, scalp, palm, sole).
Patients must have histologically or cytologically confirmed locally advanced head and neck cancer of squamous type stage III, IVA and IV B (larynx, oral cavity, oropharynx and hypopharynx or unknown primary isolated to the head and neck region) and select stage II tumors of the base of the tongue (BOT) (size more than  cm), who are appropriate for potentially curative therapy with chemoradiotherapy or surgical resection, as determined by the multidisciplinary head and neck cancer clinical care and research team
Prior chemotherapy for the current SCCHN will not be allowed; patients with second primary cancers of the head and neck who remain in remission for  years from the prior diagnosis are eligible for this study, provided they may receive full dose radiation to the current SCCHN cancer
Patients may have received induction therapy prior to definitive therapy for the current head and neck cancer
Patient with newly diagnosed or recurrent, histologic diagnosis of lung cancer or head & neck cancer (categories: oral cavity, pharynx and larynx only)
Patient must have undergone transoral resection of their T-a oropharynx primary to a negative margin, and a neck dissection(s)
Patient must not have outside nodal tissue from previous neck biopsy/neck dissections in which ECS cannot be confirmed or denied
Reirradiation targets located within the head, neck, or brain are excluded from this study
Any N stage but resectable; lymph nodes in both sides of the neck are at risk of metastatic disease, according to clinical judgment, and require irradiation; pre-treatment surgery in the neck in the forms of incisional/excisional biopsy or a multilevel neck dissection is allowed only if there is gross tumor left at the primary site
Prior malignancies at sites other than the head and neck are allowable if there has been greater than or equal to a  year disease free interval; basal cell carcinoma of the skin and in-situ cervix dysplasias are allowable within this  year interval if completely resected
Patients with prior history of head and neck radiotherapy (>  Gy) with significant areas of anticipated overlap
confirmed SCC of the head and neck, lung, or esophagus
Subjects with a diagnosis of head and neck cancer biopsy proven, and who have a scheduled appointment for definitive resection of the tumor at Thomas Jefferson University Hospital (TJUH) are eligible to participate
Participants with unknown primary SCCHN presumed to be of head and neck mucosal origin are eligible if they meet all other entry criteria
Disease status\r\n* Tumors must have NOT been completely resected, or must be locoregionally recurrent if previously resected; tumor must be deemed potentially resectable by local surgeon\r\n* MM arising from the head/neck, genitourinary, or gastrointestinal tract\r\n* Disease meets any  of  characteristics:\r\n** Regional lymph node (LN) involvement; OR\r\n** Multifocal/satellite primary disease; OR\r\n** Single localized, primary disease meeting one of the following site-specific requirements:\r\n*** Head/neck  any primary lesion if sinonasal; pTa or above for nasal or oral cavity\r\n*** Anorectal  any primary lesion\r\n*** Conjunctiva  any primary lesion T or T stage by American Joint Committee on Cancer (AJCC)\r\n*** Vaginal/cervical  any primary\r\n*** Vulvar (hair bearing surface, labia majora)  AJCC cutaneous stage IIB or higher\r\n*** Esophageal  any primary\r\n** Locoregionally recurrent following prior resection\r\n* No evidence of metastatic disease at the time of registration
Diagnosis of any of the following cancers: stage -b (includes a) oropharyngeal, hypopharyngeal, nasopharyngeal, salivary gland or oral cavity; stage -b (includes a) laryngeal; any unknown primary head and neck cancer with cervical metastasis that will be addressed with treatment to bilateral necks and mucosa; any thyroid cancer that will be addressed with treatment to the bilateral necks; or other head and neck cancers medically approved by one of our Radiation Oncology collaborating medical doctors (MDs)
Has had prior systemic therapy, targeted therapy, radiotherapy treatment or radical surgery for head and neck cancer under study
Patients undergoing free flaps for reconstruction of head and neck surgical defects at University of California (UC) Davis Medical Center (UCDMC), including but not limited to, head and neck cancer defects, osteoradionecrosis (ORN), and trauma
Patients must be diagnosed with cancer of the head and neck and must be surgical candidates
History of head injury
Completed treatment for a head or neck cancer at this institution within  months of consent OR will complete treatment for a head and neck cancer at this institution within  weeks of consent
Patient requires a neck brace for medical reasons
Patient has no history of prior neck surgery or external radiation to neck for malignant conditions
All subjects who receive a radial forearm free flaps in the included time period, including subjects with head and neck cancer, traumatic defects, chronic wounds, or any other problems that require a radical forearm free flap for reconstruction
Full range of motion in the neck
Limited neck movement
Histologically proven cancer of the head and neck cancer
Cervical or head/neck cancer diagnosis in the past  years
Patients with a definitive, curative treatment plan consisting of chemoradiation for head & neck cancer\r\n* Surgery, if required, must be limited to: diagnostic biopsy
Have a clinical stage II-IV head and neck carcinoma
Diagnosed with head and neck cancer, which will be primarily nasopharyngeal, and scheduled to undergo intensity-modulated radiation therapy (IMRT) or proton with or without concurrent chemotherapy at MD Anderson or Fudan University
History of xerostomia prior to head and neck radiation therapy or history of Sjgren's disease or another underlying systemic illness known to cause xerostomia
Previous receipt of head and neck irradiation
Patients with head and neck cancer who are undergoing either flap or nonflap surgery (limited to parotidectomy, hard palate maxillectomy and glossectomy, mandibulectomy, and any procedure with neck dissection) at MD Anderson Cancer Center
>  months post-treatment of head and neck cancer (HNC)
Diagnosed with head and neck cancer, which will be primarily oropharyngeal, and scheduled to undergo intensity modulated radiation therapy (IMRT) with or without concurrent chemotherapy at M. D. Anderson
History of xerostomia prior to head and neck radiation therapy or history of Sjgren's disease or another underlying systemic illness known to cause xerostomia
Patients who will undergo complex head and neck surgery in addition to the TORS procedure requiring reconstruction with a free flap
Personal history of lung cancer or head and neck cancer
Patients must be receiving cisplatin therapy for a non-head and neck malignancy in total doses >=  mg/m^
Patients must be scheduled to receive RT or CRT as definitive treatment or adjuvant RT or CRT treatment post-surgery per surgeon or Head and Neck Cancer (HNC) Tumor Board decision
Must have anatomically intact parotid glands and at least one submandibular gland; a focused (head/neck) history and exam conducted by a physician or dentist within the past year is required
History of xerostomia, Sjogrens disease or other illness known to affect salivation prior to head/neck radiation
Personal history of lung cancer or head and neck cancer
Evidence of current disease with lung cancer or head and neck cancer
Patients may have a prior history of lung cancer or head and neck cancer treated with curative intent, provided that there has been no evidence of disease (NED) for >  year; the qualifying autofluorescence (AF) bronchoscopy must be negative for malignancy
Diagnosed with melanoma or lymphoma cancer of the head and neck
Group  patients: Presence of a suspicious metastatic lesion or suspicious for recurrent disease in the head and neck region
Confirmed or suspected head and neck tumor (benign or malignant)
Adult patients seen in the Head and Neck Tumor Clinic who will require laryngoscopy in the operating room for diagnosis and staging of known or suspected tumors of the upper aerodigestive tract (UADT)
Patients with histologically proven diagnosis of head and neck cancer or patients with tumors strongly suspicious for head and neck cancer due to clinical features or FNA (fine needle aspiration) cytology assessment
Patients with a history of head and neck cancer or oral premalignant disease but without any clinical evidence of disease
Patients diagnosed with any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection, including a (modified) neck dissection
Participant with unilateral or bilateral neck dissection planned for care; an N neck must be planned to be dissected for the patient to be eligible; the N neck can be either ipsilateral to the head and neck tumor or the contralateral N neck if a bilateral neck dissection is planned
Participant with at least one neck that is clinically N as defined by clinical exam (physical exam with CT and/or MRI as the gold standard of the N neck); stages T, T, or T. NN, excluding Nc for bilateral disease based on criteria from the American Joint Commission on Cancer
Participant in whom it may be considered a viable clinical option to perform neck dissection when primary cancers are at high risk for neck metastasis (see definition above);\r\n* These will include: ) oral cavity cancer; ) oropharynx cancer, including base of tongue and tonsil cancers; ) larynx cancer; or ) supraglottic cancer
Patient with tumors in the head and neck that are not SCC
Patients diagnosed with any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection; patients with recurrent disease or a new primary will be allowed
Patients must have had pathologic lymph nodes in the neck, axillary or inguinal area (do not need to be biopsy proven) from either leukemias, lymphomas; head and neck cancers (e.g. tonsillar, nasopharynx, tongue carcinoma), breast cancer or melanoma; or thyroid cancer for thyroid ablation therapy; any other more infrequent cancer with nodal metastasis in the neck, axilla, and inguinal regions is eligible as well as the primary goal is to image pathological (i.e. hypermetabolic) lymph nodes
Patients with indications for initial total thyroidectomy (TT) including preexisting hypothyroidism or history of head and neck radiation when <  years old will be excluded.
Patients with a variety of malignancies (i.e., melanoma, sarcoma, colon, head and neck,\r\nrenal, breast, lung, ovary, liver)
Patients with a diagnosis of head and neck cancer biopsy proven, and who have a scheduled appointment for definitive resection of the tumor at Thomas Jefferson University Hospital (TJUH) are eligible to participate
Patients with neck dissection connected to upper aerodigestive tract
Patients undergoing bilateral neck dissection
Patients undergoing neck skin defect reconstruction
Pre-intervention:  patient records between January ,  and December ,  are subject to review; the first  records with a diagnoses of each cancer type: head and neck, lung, prostate, or breast will be utilized for the review
Diagnosis of any of the following cancers: stage -b oropharyngeal, hypopharyngeal, nasopharyngeal, salivary gland or oral cavity; stage -b laryngeal; any unknown primary head and neck cancer with cervical metastasis that will be addressed with treatment to bilateral necks and mucosa; or other head and neck cancers medically approved by one of our Radiation Oncology collaborating medical doctors (MDs) (Arms  and )
Planned RT to the head/neck
Patients must have histologically confirmed head-and-neck, lung, or prostate tumors
Subjects have head and neck cancer as defined in history and physical
History of prior surgery on the oropharynx, neck, esophagus, or stomach